First-in-human study of AMG 820, a monoclonal anti-colony-stimulating factor 1 receptor antibody, in patients with advanced solid tumors

Clinical Cancer Research

Volumn 23, Issue 19, 2017, Pages 5703-5710

  Papadopoulos, Kyriakos P ^a,g   Gluck, Larry ^b   Martin, Lainie P ^c   Olszanski, Anthony J ^c   Tolcher, Anthony W ^d   Ngarmchamnanrith, Gataree ^e   Rasmussen, Erik ^e   Amore, Benny M ^e   Nagorsen, Dirk ^e   Hill, John S ^e,f   Stephenson, Joe ^b  

^a Division of Hematology and Medical Oncology   (United States)

^b GREENVILLE HOSPITAL SYSTEM   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d South Texas Accelerated Research Therapeutics (START)   (United States)

^e AMGEN INC   (United States)

^f PHARMACYCLICS INC   (United States)

^g South Texas Accelerated Research Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMG 820; ASPARTATE AMINOTRANSFERASE; COLONY STIMULATING FACTOR 1; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; CSF1R PROTEIN, HUMAN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; IL36A PROTEIN, HUMAN; INTERLEUKIN 1;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ANUS CANCER; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLURRED VISION; CLINICAL ARTICLE; COLORECTAL CANCER; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEARING IMPAIRMENT; HUMAN; HYPERTENSION; LIVER METASTASIS; LOW DRUG DOSE; MACROPHAGE; MALE; MAXIMUM PLASMA CONCENTRATION; NON SMALL CELL LUNG CANCER; PANCREAS ISLET CELL TUMOR; PARAGANGLIOMA; PERIORBITAL EDEMA; PRIORITY JOURNAL; SIDE EFFECT; SOLID MALIGNANT NEOPLASM; TREATMENT OUTCOME; TUMOR VOLUME; ADVERSE DRUG REACTION; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; GENETICS; IMMUNOLOGY; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; PATHOLOGY; PHASE 1 CLINICAL TRIAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INTERLEUKIN-1; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; TREATMENT OUTCOME;

EID: 85032011757     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-3261     Document Type: Article

References (32)

1. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66:605–12.
2. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71–8.
3. Jinushi M, Komohara Y. Tumor-associated macrophages as an emerging target against tumors: creating a new path from bench to bedside. Biochim Biophys Acta 2015;1855:123–30.
4. Kitamura T, Qian BZ, Pollard JW. Immune cell promotion of metastasis. Nat Rev Immunol 2015;15:73–86.
5. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001;193:727–40.
6. Maher MG, Sapi E, Turner B, Gumbs A, Perrotta PL, Carter D, et al. Prognostic significance of colony-stimulating factor receptor expression in ipsilateral breast cancer recurrence. Clin Cancer Res 1998;4:1851–6.
7. Hammes LS, Tekmal RR, Naud P, Edelweiss MI, Kirma N, Valente PT, et al. Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease. Gynecol Oncol 2008;110:445–51.
8. Soares MJ, Pinto M, Henrique R, Vieira J, Cerveira N, Peixoto A, et al. CSF1R copy number changes, point mutations, and RNA and protein overexpression in renal cell carcinomas. Mod Pathol 2009;22:744–52.
9. Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E, et al. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science 2008;320:807–11.
10. Wei S, Nandi S, Chitu V, Yeung YG, Yu W, Huang M, et al. Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells. J Leukoc Biol 2010;88: 495–505.
11. West RB, Rubin BP, Miller MA, Subramanian S, Kaygusuz G, Montgomery K, et al. A landscape effect in tenosynovial giant-cell tumor from activation ofCSF1expressionbyatranslocationinaminorityoftumorcells.ProcNatl Acad Sci U S A 2006;103:690–5.
12. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 2014;25:846–59.
13. Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med 2015;373:428–37.
14. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011; 1:54–67.
15. Mok S, Koya RC, Tsui C, Xu J, Robert L, Wu L, et al. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res 2014;74:153–61.
16. Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 2014;74:5057–69.
17. Hume DA, MacDonald KP. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 2012;119:1810–20.
18. Houot R, Schultz LM, Marabelle A, Kohrt H. T-cell-based immunotherapy: adoptive cell transfer and checkpoint inhibition. Cancer Immunol Res 2015;3:1115–22.
19. Bristol-Myers Squibb. Yervoy (ipilimumab). Full prescribing information. Princeton, NJ: Bristol-Myers Squibb; 2015.
20. Bristol-Myers Squibb. Opdivo (nivolumab). Full prescribing information. Princeton, NJ: Bristol-Myers Squibb; 2016.
21. Merck & Co., Inc. Keytruda (pembrolizumab). Full prescribing information. Whitehouse Station, NJ: Merck & Co., Inc.; 2015.
22. MacDonald KP, Palmer JS, Cronau S, Seppanen E, Olver S, Raffelt NC, et al. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood 2010;116:3955–63.
23. Lohela M, Casbon AJ, Olow A, Bonham L, Branstetter D, Weng N, et al. Intravital imaging reveals distinct responses of depleting dynamic tumor-associated macrophage and dendritic cell subpopulations. Proc Natl Acad Sci U S A 2014;111:E5086–95.
24. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45: 228–47.
25. ECOG-ACRIN Cancer Research Group. ECOG Performance status. Available from: http://www.ecog.org/general/perf_stat.html.
26. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Bethesda, MD: National Institutes of Health. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010–06-14_QuickReference_5x7.pdf.
27. Radi ZA, Koza-Taylor PH, Bell RR, Obert LA, Runnels HA, Beebe JS, et al. Increased serum enzyme levels associated with Kupffer cell reduction with no signs of hepatic or skeletal muscle injury. Am J Pathol 2011;179:240–7.
28. Bartocci A, Mastrogiannis DS, Migliorati G, Stockert RJ, Wolkoff AW, Stanley ER. Macrophages specifically regulate the concentration of their own growth factor in the circulation. Proc Natl Acad Sci U S A 1987; 84:6179–83.
29. Sauter KA, Pridans C, Sehgal A, Tsai YT, Bradford BM, Raza S, et al. Pleiotropic effects of extended blockade of CSF1R signaling in adult mice. J Leukoc Biol 2014;96:265–74.
30. Lee MS, Kopetz S. Novel therapies in development for metastatic colorectal cancer. Gastrointest Cancer Res 2014;7:S2–7.
31. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–54.
32. Gomez-Roca CA, Cassier PA, Italiano A, Cannarile M, Ries C, Brillouet A, et al. Phase I study of RG7155, a novel anti-CSF1R antibody, in patients with advanced/metastatic solid tumors. J Clin Oncol 33:15s, 2015 (suppl; abstr 3005).